CNTA 주가 차트
CNTA 재무
Centessa Pharmaceuticals PLC
$40.5
0%
$0
종가: Jun 25, 16:00:00 GMT-4
$40.5
0%
$0
애프터마켓: Jun 25, 20:00:00 GMT-4
뒤로
Centessa Pharmaceuticals PLC (CNTA) 재무
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
CNTA 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
Centessa Pharmaceuticals PLC의 주요 재무제표는 무엇인가요?
CNTA의 주요 재무 비율은 무엇인가요?
Centessa Pharmaceuticals PLC의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Centessa Pharmaceuticals PLC은 수익성이 있나요?
Centessa Pharmaceuticals PLC에 부채가 있나요?
Centessa Pharmaceuticals PLC의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$40.5
시가
$40.14
일일 범위
$40 - $40.56
52주 범위
-
거래량
11.2M
평균 거래량
--
배당수익률
--
EPS(TTM)
--
시가총액
--
CNTA란 무엇인가요?
Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. The company is headquartered in Altrincham, Cheshire and currently employs 118 full-time employees. The company went IPO on 2021-05-28. The firm is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. The company also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
